Overview The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy Status: Withdrawn Trial end date: 2023-05-01 Target enrollment: Participant gender: Summary The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality. Phase: Phase 3 Details Lead Sponsor: Asahi Kasei Pharma America Corporation